Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.43 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.43 |
| ▸ | BCHE | P06276 | 1/20 | 0.42 |
| ▸ | BUB1 | O43683 | 1/20 | 0.39 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.34 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.34 |
| ▸ | ATR | Q13535 | 1/20 | 0.33 |
| ▸ | HTR6 | P50406 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10225711 | 0.89 | HSP90AA1 (0.42) | HSP90AA1HSP90AB1BCHEBUB1PIK3R1 | |
| SCHEMBL367386 | 0.82 | HSP90AA1 (0.44) | HSP90AA1HSP90AB1BCHEBUB1PIK3R1 | |
| SCHEMBL1442828 | 0.79 | HSP90AA1 (0.42) | HSP90AA1HSP90AB1BCHEBUB1PIK3R1 | |
| SCHEMBL3412038 | 0.77 | HSP90AA1 (0.43) | HSP90AA1HSP90AB1BCHEBUB1PIK3R1 | |
| SCHEMBL15417736 | 0.76 | HSP90AA1 (0.47) | HSP90AA1HSP90AB1BCHEBUB1PIK3R1 | |
| SCHEMBL163016 | 0.76 | HSP90AA1 (0.47) | HSP90AA1HSP90AB1BCHEBUB1PIK3R1 | |
| SCHEMBL4916320 | 0.76 | HSP90AA1 (0.47) | HSP90AA1HSP90AB1BCHEBUB1PIK3R1 | |
| SCHEMBL19547655 | 0.76 | HSP90AA1 (0.40) | HSP90AA1HSP90AB1BCHEBUB1PIK3R1 | |
| SCHEMBL23664159 | 0.75 | HSP90AA1 (0.44) | HSP90AA1HSP90AB1BCHEBUB1PIK3R1 | |
| SCHEMBL19204908 | 0.75 | HSP90AA1 (0.46) | HSP90AA1HSP90AB1BCHEBUB1PIK3R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115093423-A | Synthesis method of naphthoporphyrin with different substituents and preparation method of metal complex thereof | 江苏大学 | 2022-09-23 | — | — | CN | claimed |
| EP-4747247-A1 | NOVEL FATTY ACID AMIDE HYDROLASE MODULATORS, COMPOSITIONS COMPRISING THE SAME AND USES THEREOF | Apogee Pharmaceuticals, Inc. (CA) | 2026-05-27 | — | — | EP | disclosed |
| US-12637468-B2 | Substituted [1,2,4]triazolo[4,3-b]pyridazines as GABAA receptor modulators | Shanghai Simr Biotechnology Co., Ltd. (CN) | 2026-05-26 | — | — | US | disclosed |
| US-20250361237-A1 | 1,4-DIHYDROBENZO[D]PYRAZOLO[3,4-F][1,3]DIAZEPINE DERIVATIVES AND RELATED COMPOUNDS AS LRRK2, NUAK1 AND/OR TYK2 KINASE MODULATORS FOR THE TREATMENT OF E.G. AUTOIMMUNE DISEASE | ORIGENIS GMBH (DE) | 2025-11-27 | — | — | US | disclosed |
| US-12410137-B2 | Fatty acid amide hydrolase modulators, compositions comprising the same and uses thereof | APOGEE PHARMACEUTICALS, INC. (CA) | 2025-09-09 | — | — | US | disclosed |
| US-20250215013-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS AS PARP INHIBITORS AND THE USE THEREOF | IMPACT THERAPEUTICS (SHANGHAI), INC. (CN) | 2025-07-03 | — | — | US | disclosed |
| US-20250129027-A1 | FATTY ACID AMIDE HYDROLASE MODULATORS, COMPOSITIONS COMPRISING THE SAME AND USES THEREOF | APOGEE PHARMACEUTICALS, INC. (CA) | 2025-04-24 | — | — | US | disclosed |
| WO-2025015420-A1 | NOVEL FATTY ACID AMIDE HYDROLASE MODULATORS, COMPOSITIONS COMPRISING THE SAME AND USES THEREOF | APOGEE PHARMACEUTICALS, INC. (CA) | 2025-01-23 | — | — | WO | disclosed |
| CN-118344346-A | Heterocyclic compounds and their use | 武田药品工业株式会社 | 2024-07-16 | — | — | CN | disclosed |
| CN-118290408-A | Heterocyclic compounds and their use | 武田药品工业株式会社 | 2024-07-05 | — | — | CN | disclosed |
| US-6358948-B1 | ANTICARCINOGENIC AND ANTITUMOR AGENTS AGAINST BREAST, PITUITARY, OVARIAN, ENDOMETRIUM, AND PROSTATE CANCER; BENIGN PROSTATIC HYPERPLASIA; CONTRACEPTIVES | AMERICAN HOME PRODUCTS CORPORATION | 2002-03-19 | — | — | US | disclosed |
| EP-0937072-B1 | THIENYLCYCLOHEXANONE DERIVATIVES AS LIGANDS OF THE GABA A alpha5 RECEPTOR SUBTYPE | MERCK SHARP & DOHME (GB) | 2002-01-09 | — | — | EP | disclosed |
| US-6262103-B1 | ALZHEIMER'S DISEASE. | MERCK SHARP & DOHME LIMITED (GB) | 2001-07-17 | — | — | US | disclosed |
| EP-0975592-A1 | BENZYLOXY PRODIGIOSINE COMPOUNDS | PHARMACIA & UPJOHN S.p.A. (IT) | 2000-02-02 | — | — | EP | disclosed |
| US-6020345-A | Pyridin-2-yl-methylamine derivatives, method of preparing and application as medicine | PIERRE FABRE MEDICAMENT (FR) | 2000-02-01 | — | — | US | disclosed |
| EP-0946546-A1 | PYRIDIN-2-YL-METHYLAMINE DERIVATIVES, METHOD OF PREPARING AND APPLICATION AS MEDICINE | PIERRE FABRE MEDICAMENT (FR) | 1999-10-06 | — | — | EP | disclosed |
| EP-0937072-A1 | THIENYLCYCLOHEXANONE DERIVATIVES AS LIGANDS OF THE GABA A? $g(a)5 RECEPTOR SUBTYPE | MERCK SHARP & DOHME LTD. (GB) | 1999-08-25 | — | — | EP | disclosed |
| WO-1999040069-A1 | BENZYLOXY PRODIGIOSINE COMPOUNDS | PHARMACIA & UPJOHN S.P.A. (IT) | 1999-08-12 | — | — | WO | disclosed |
| WO-1998022459-A1 | PYRIDIN-2-YL-METHYLAMINE DERIVATIVES, METHOD OF PREPARING AND APPLICATION AS MEDICINE | PIERRE FABRE MEDICAMENT (FR) | 1998-05-28 | — | — | WO | disclosed |
| WO-1998018792-A1 | THIENYLCYCLOHEXANONE DERIVATIVES AS LIGANDS OF THE GABAA α5 RECEPTOR SUBTYPE | MERCK SHARP & DOHME LIMITED (GB) | 1998-05-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250129027-A1 | FATTY ACID AMIDE HYDROLASE MODULATORS, COMPOSITIONS COMPRISING THE SAME AND USES THEREOF | FAAH, FAAH2, MGLL | HSP90AA1 1068/4885HSP90AB1 1122/4885BCHE 353/4885 |
| US-12637468-B2 | Substituted [1,2,4]triazolo[4,3-b]pyridazines as GABAA receptor modulators | GABRA6, GABRA1, GABRB1 | HSP90AA1 3634/4885HSP90AB1 3401/4885BCHE 1862/4885 |
| US-20250215013-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS AS PARP INHIBITORS AND THE USE THEREOF | PARP1, PARP2, PARP3 | HSP90AA1 3173/4885HSP90AB1 3328/4885BCHE 4199/4885 |
| US-12410137-B2 | Fatty acid amide hydrolase modulators, compositions comprising the same and uses thereof | FAAH, FAAH2, MGLL | HSP90AA1 1068/4885HSP90AB1 1122/4885BCHE 353/4885 |
| US-20250361237-A1 | 1,4-DIHYDROBENZO[D]PYRAZOLO[3,4-F][1,3]DIAZEPINE DERIVATIVES AND RELATED COMPOUNDS AS LRRK2, NUAK1 AND/OR TYK2 KINASE MODULATORS FOR THE TREATMENT OF E.G. AUTOIMMUNE DISEASE | NUAK1, TYK2, MARK1 | HSP90AA1 2681/4885HSP90AB1 2426/4885BCHE 2906/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.